中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
2期
1-2
,共2页
郑利民%罗立勤%杜鹏程%霍建新%杨建华%张琳%王俊琴%包春华
鄭利民%囉立勤%杜鵬程%霍建新%楊建華%張琳%王俊琴%包春華
정이민%라립근%두붕정%곽건신%양건화%장림%왕준금%포춘화
频域OCT%曲安奈德%视网膜静脉阻塞%糖尿病视网膜病变%葡萄膜炎%黄斑水肿
頻域OCT%麯安奈德%視網膜靜脈阻塞%糖尿病視網膜病變%葡萄膜炎%黃斑水腫
빈역OCT%곡안내덕%시망막정맥조새%당뇨병시망막병변%포도막염%황반수종
Spectra Domain OCT%Triamcinolone%Retinal Vein Occlusion%Diabetic retinopathy%Uveitis%Macular Edema
目的通过频域OCT观察玻璃体腔注射曲安奈德(TA)治疗黄斑水肿的临床疗效.方法回顾性分析46例眼科常规检查及经FFA和频域OCT查均确诊为黄斑水肿,视力≤0.6,黄斑中心凹厚度(CMT)≥250μm的患者46只眼纳入观察,进行玻璃体腔注射TA(4mg,0.1mL)治疗.比较治疗前和治疗后1d及1,2,4,8,12,24周最佳矫正视力(BCVA)改变;治疗前和治疗后1,2,4,8,12,24周的黄斑中心凹厚度(CMT)、黄斑中心容积(CMV)、黄斑区平均厚度(AVG)的改变.结果在治疗后视显提高,术后各时间点(P=0.000)均具有统计学意义,BCVA各点分别为:4周(0.3916±0.2564);8周(0.5668±0.1835);12周(0.5314±0.1996),视力基本持平,24周(0.3853±0.2024)缓慢下降.CMT方面,较基线比,在治疗后CMT明显降低,术后各时间点(P=0.000)均具有统计学意义.与基线相比, CMV、AVG两具有显著改变.BCVA分别与CMT、CMV、AVG呈负相关.结论玻璃体腔注射TA治疗黄斑水肿均可明显改善,减轻黄斑水肿.BCVA分别与CMT、CMV、AVG呈负相关,CMV、AVG也可反映治疗效果,但敏感性不及CMT
目的通過頻域OCT觀察玻璃體腔註射麯安奈德(TA)治療黃斑水腫的臨床療效.方法迴顧性分析46例眼科常規檢查及經FFA和頻域OCT查均確診為黃斑水腫,視力≤0.6,黃斑中心凹厚度(CMT)≥250μm的患者46隻眼納入觀察,進行玻璃體腔註射TA(4mg,0.1mL)治療.比較治療前和治療後1d及1,2,4,8,12,24週最佳矯正視力(BCVA)改變;治療前和治療後1,2,4,8,12,24週的黃斑中心凹厚度(CMT)、黃斑中心容積(CMV)、黃斑區平均厚度(AVG)的改變.結果在治療後視顯提高,術後各時間點(P=0.000)均具有統計學意義,BCVA各點分彆為:4週(0.3916±0.2564);8週(0.5668±0.1835);12週(0.5314±0.1996),視力基本持平,24週(0.3853±0.2024)緩慢下降.CMT方麵,較基線比,在治療後CMT明顯降低,術後各時間點(P=0.000)均具有統計學意義.與基線相比, CMV、AVG兩具有顯著改變.BCVA分彆與CMT、CMV、AVG呈負相關.結論玻璃體腔註射TA治療黃斑水腫均可明顯改善,減輕黃斑水腫.BCVA分彆與CMT、CMV、AVG呈負相關,CMV、AVG也可反映治療效果,但敏感性不及CMT
목적통과빈역OCT관찰파리체강주사곡안내덕(TA)치료황반수종적림상료효.방법회고성분석46례안과상규검사급경FFA화빈역OCT사균학진위황반수종,시력≤0.6,황반중심요후도(CMT)≥250μm적환자46지안납입관찰,진행파리체강주사TA(4mg,0.1mL)치료.비교치료전화치료후1d급1,2,4,8,12,24주최가교정시력(BCVA)개변;치료전화치료후1,2,4,8,12,24주적황반중심요후도(CMT)、황반중심용적(CMV)、황반구평균후도(AVG)적개변.결과재치료후시현제고,술후각시간점(P=0.000)균구유통계학의의,BCVA각점분별위:4주(0.3916±0.2564);8주(0.5668±0.1835);12주(0.5314±0.1996),시력기본지평,24주(0.3853±0.2024)완만하강.CMT방면,교기선비,재치료후CMT명현강저,술후각시간점(P=0.000)균구유통계학의의.여기선상비, CMV、AVG량구유현저개변.BCVA분별여CMT、CMV、AVG정부상관.결론파리체강주사TA치료황반수종균가명현개선,감경황반수종.BCVA분별여CMT、CMV、AVG정부상관,CMV、AVG야가반영치료효과,단민감성불급CMT
Objective To observe the efficiency of IVTA for the treatment of ME by spectra domain OCT. Methods A total of 46 eyes with ME were observed. All patients were diagnosed expecially by FFA and spectra domain OCT, with vision≤0.6 and CMT≥250μm. All received intravitreal injection of 4mg/0.1mL of TA. BCVA, CMT, CMV, and AVG were compared before and after treatment. Results After treatment, BCVA were significantly increased in each time point(P=0.000), BCVA in 4 (BCVA=0.3916±0.2564), 8 (BCVA=0.5668±0.1835), 12 (BCVA=0.5314±0.1996) weeks, were similar. After treatment, compared with baseline, the changes of CMT, CMV and AVG were significantly increased in each time point (P=0.000). Conclusion IVTA for the treatment of ME could increase BCVA and reduce ME instinctively. CMT can reveal the effect of treatment better than CMV and AVG.